KLAC KLA Corporation

Q1 2025 10-Q

Filed: May 1, 2025Period ending Mar 31, 2025

Health Care

Optical Instruments & LensesSEC EDGAR

KLA Corporation (KLAC) 10-Q quarterly report for Q1 2025, filed with SEC EDGAR on May 1, 2025 for the fiscal period ending Mar 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q1 2025 10-Q

Management Discussion & Analysis

• Working capital $6.04B as of Mar 31, 2025, up $664.7M from $5.37B on June 30, 2024
• Cash, cash equivalents, and marketable securities $4.03B plus $1.50B available under Revolving Credit Facility

+3 more insights

Risk Factors

• New risk: potential repurchase obligation under Senior Notes triggered by downgrade by 2+ rating agencies, requiring 101% principal repayment plus interest
• Material update: Revolving Credit Facility interest rate now linked to sustainability KPIs on GHG emissions and renewable electricity usage

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$2.8B

Net Income

$946M

Net Margin

33.3%

Source: XBRL data from KLA Corporation Q1 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other KLA Corporation Quarterly Reports

Q4 2025 10-Q

Q3 2025 10-Q

Get deeper insights on KLA Corporation

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.